Medicalgorithmics SA (MDG) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

24.29 k

Shareholding (Mar 2020)

FII

0.26%

Held by 1 FIIs

DII

99.74%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Net Sales has grown by an annual rate of -26.13% and Operating profit at 9.04% over the last 5 years

The company has declared Negative results for the last 6 consecutive quarters

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 338 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.25

Return on Equity

-23.34%

Price to Book

5.13

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Mar 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.79%

6 Months

39.07%

1 Year

92.44%

2 Years

3.15%

3 Years

174.8%

4 Years

77.98%

5 Years

63.18%

Medicalgorithmics SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-26.13%

EBIT Growth (5y)

9.04%

EBIT to Interest (avg)

-17.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.03

Sales to Capital Employed (avg)

0.38

Tax Ratio

1.91%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.26%

ROCE (avg)

0.27%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.85

EV to EBIT

-20.83

EV to EBITDA

-23.65

EV to Capital Employed

4.25

EV to Sales

14.13

PEG Ratio

Dividend Yield

ROCE (Latest)

-20.41%

ROE (Latest)

-19.29%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2020

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.26%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 15.25% vs 13.46% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 8.70% vs -119.05% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.80",
          "val2": "5.90",
          "chgp": "15.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-4.90",
          "chgp": "26.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-4.60",
          "chgp": "8.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-671.30%",
          "val2": "-891.90%",
          "chgp": "22.06%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -44.32% vs -31.26% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2,583.33% vs -102.35% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.00",
          "val2": "43.10",
          "chgp": "-44.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.80",
          "val2": "2.50",
          "chgp": "-772.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.10",
          "val2": "-0.60",
          "chgp": "-2,583.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-852.60%",
          "val2": "3.20%",
          "chgp": "-85.58%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

6.80

5.90

15.25%

Operating Profit (PBDIT) excl Other Income

-3.60

-4.90

26.53%

Interest

0.30

0.10

200.00%

Exceptional Items

0.00

Consolidate Net Profit

-4.20

-4.60

8.70%

Operating Profit Margin (Excl OI)

-671.30%

-891.90%

22.06%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is 15.25% vs 13.46% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 8.70% vs -119.05% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

24.00

43.10

-44.32%

Operating Profit (PBDIT) excl Other Income

-16.80

2.50

-772.00%

Interest

0.20

0.10

100.00%

Exceptional Items

0.00

0.70

-100.00%

Consolidate Net Profit

-16.10

-0.60

-2,583.33%

Operating Profit Margin (Excl OI)

-852.60%

3.20%

-85.58%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -44.32% vs -31.26% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2,583.33% vs -102.35% in Dec 2023

All Annual Results

Company CV

About Medicalgorithmics SA

Medicalgorithmics SA

Pharmaceuticals & Biotechnology

Medicalgorithmics SA is a Poland-based company engaged in the advanced medical equipment and technology industry. The Company develops and manufactures system for the diagnosis of heart arrhythmia. Its product, named PocketECG, is used for remote monitoring of cardiac disorders, arrhythmia diagnosis and monitoring of heart, as well as is used for clinical drugs trials for cardiac safety. In addition, Medicalgorithmics SA provides services in the field of information technology and biotechnology, scientific research and development of natural sciences. Moreover, the Company works on the several projects, such as a device for tele-rehabilitation cardiology, software for optimizing repetitive task in hospitals, as well as devices and systems for remote description of the electrocardiography (ECG). It operates through MEDICALGORITHMICS US HOLDING CORPORATION and Medi-Lynx Cardiac Monitoring LLC and Medi-Lynx Cardiac Monitoring LLC.

Company Coordinates

Company Details

Al. Jerozolimskie 81 , WARSZAWA None : 02-001

Tel: 48 22 825124948 697 613020

http://www.medicalgorithmics.com/

Registrar Details